Connect with us
  • Elysium

Spinal

Christopher & Dana Reeve Foundation appoint new senior figure

Dr Marco Baptista joins as chief scientific officer, moving from the Michael J. Fox Foundation

Published

on

A leading figure in neuroscience has joined the Christopher & Dana Reeve Foundation to help lead its mission to advance cures for spinal cord injury (SCI) and paralysis. 

Dr Marco Baptista joins as Chief Scientific Officer and will provide scientific and innovative oversight of the nonprofit’s collaborative approach to accelerating the field toward meaningful therapeutics.

Dr Baptista joins the Reeve Foundation as it celebrates 40 years of progress and the seismic shift that it helped steer to move the field of SCI research to its current fast-developing state.

To date, the Foundation has funded more than $140million of research around the world, uniting the brightest minds in the field to help usher a new era of scientific inquiry focused on developing and delivering treatments that are, today, pushing the world toward real cures.

“What began as a grassroots movement by pioneers who refused to accept the long-standing dogma that the spinal cord, once injured, could never be repaired is today an exciting field primed to cross the critical threshold of laboratory science to real-world therapies widely available to our community,” said Maggie Goldberg, President and CEO of the Reeve Foundation. 

“Dr Baptista brings a special blend of neuroscience acumen to our organization, our research collaborative and the community of people living with or caring for someone with SCI. His strong industry knowledge will move us from the bench to the bedside. We’re honored to have him aboard.”

Dr Baptista joins the Reeve Foundation from the Michael J. Fox Foundation for Parkinson’s Research, where he served as Vice President of Research Programs. 

Dr Marco Baptista

In his decade with the Fox Foundation, he led priority research around LRRK2, a major genetic mutation that can increase the chances of developing Parkinson’s disease – an area of study that had also been the focus of his efforts in the pharmaceutical industry, where he spent five years working at Schering-Plough, and then Merck when it acquired the company in 2009. 

“Joining the Reeve Foundation is a natural extension of my long and deep commitment both to studying the central nervous system and my desire to help people,” said Dr Baptista. 

“With the Foundation’s reputation and impact in care and scientific research for those living with SCI, it’s an exciting place to be at the right moment in time.

“The Reeve Foundation took this field from obscurity to one of real promise. Now, thanks in part to its funding of basic research, we’ve generated a solid understanding of the biological mechanisms underlying SCI and paralysis, and the drive toward cures is not a hammer looking at all the world as a nail. 

“Rather, we can identify the studies that stand the greatest chances of success, learn quickly from those that fail, and remove barriers to our greatest shared goal: long-awaited cures.”

In his new role, Dr Baptista will manage the Foundation’s research portfolio, which includes a number of high-profile endeavours with the potential to swiftly move the needle toward clinically approved and market-ready products. These include:

  • The Big Idea, a groundbreaking study at the University of Louisville investigating epidural stimulation to dramatically improve quality of life through improved cardiovascular health, bladder control, and other autonomic functions – and voluntary movement, including the previously impossible task of walking over ground. The trial is on track to be fully enrolled this summer.
  • Research-driven financial investments, such as a partnership with ONWARD, a Netherlands-based company that has developed breakthrough technology currently in global clinical trials that deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions; and Axonis, an emerging biotech advancing breakthrough research to develop therapies for neurological disorders.
  • A strategic partnership with the UK’s International Spinal Research Trust (ISRT) to co-develop a research strategy with a joint focus on chronic injury, combination approaches and clinical translation. At the core of the alliance is a collaborative blueprint that aims to establish a framework for decision-making, planning and governance to advance the most promising therapies from the preclinical stage through clinical trials and into medical practice. Most recently, the Reeve Foundation and ISRT announced joint funding for a newly created translational award totaling $1.3 million, focused on restoring function in chronic SCI through novel circuit formation.
  • Support for the North American Clinical Trials Network (NACTN), a research network established by the Foundation that to date has enrolled more than 1000 subjects to a data registry; it also actively collaborates with other clinical trial networks in Europe and Canada. Dr. Baptista will liaise with the principal investigators leading this important, ongoing research.

 

Newsletter

Sign up for the NR Times newsletter
I would like to receive by email other offers, promotions and services from Aspect Publishing Ltd and its group companies.*

Trending